CNS disorders therapeutic - AMRI/Bristol-Myers Squibb

Drug Profile

CNS disorders therapeutic - AMRI/Bristol-Myers Squibb

Alternative Names: Triple reuptake inhibitor

Latest Information Update: 09 Sep 2016

Price : $50

At a glance

  • Originator AMRI
  • Developer AMRI; Bristol-Myers Squibb
  • Class
  • Mechanism of Action Biogenic amine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II CNS disorders

Most Recent Events

  • 09 Sep 2016 CNS disorders therapeutic is still in phase II development for CNS disorders (AMRI pipeline, September 2016)
  • 25 May 2011 Phase-II clinical trials in CNS disorders (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top